- Home
- STUB vs LMAT Comparison
STUB vs LMAT Comparison
Compare STUB & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STUB | LMAT |
|---|---|---|
| Founded | 2000 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2025 | 2006 |
Fundamental Metrics
Financial Performance| Metric | STUB | LMAT |
|---|---|---|
| Price | $5.97 | $82.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | $10.54 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 6.0M | 216.4K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 1.21% |
| EPS Growth | N/A | ★ 30.57 |
| EPS | 0.06 | ★ 1.42 |
| Revenue | ★ $1,745,188,000.00 | $249,602,000.00 |
| Revenue This Year | $15.84 | $10.79 |
| Revenue Next Year | $9.82 | $9.54 |
| P/E Ratio | $99.33 | ★ $58.43 |
| Revenue Growth | N/A | ★ 13.53 |
| 52 Week Low | $5.22 | $78.22 |
| 52 Week High | $21.49 | $118.01 |
Technical Indicators
Market Signals| Indicator | STUB | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 56.93 |
| Support Level | $5.74 | $82.58 |
| Resistance Level | $6.43 | $88.54 |
| Average True Range (ATR) | 0.27 | 2.23 |
| MACD | 0.13 | 0.43 |
| Stochastic Oscillator | 66.52 | 88.63 |
Price Performance
Historical ComparisonAbout STUB StubHub Holdings Inc.
Stubhub Holdings Inc operates a ticketing marketplace for live events where fans can buy tickets from sellers of all types through its StubHub and viagogo websites and mobile applications. The company generates majority of its revenue from United States.
About LMAT LeMaitre Vascular Inc.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.